PDCD1 and neoplasm: Few other recent studies have confirmed temporal changes of the TME during PD-1 inhibitor therapy between immune subpopulations but also for tumor mutational burden, T-cell receptor (TCR) repertoire, immune-related genes, proliferation-associated and chemokine genes, neoantigen immunogenicity landscapes, and tumor clonal populations [21–25].